PALO ALTO, Calif., Oct. 10, 2018 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD) today announced the closing on October 9, 2018 of its initial public offering of 9,000,000 shares of common stock at a price to the public of $10.00 per share. The gross proceeds to Kodiak, before deducting underwriting discounts and commissions and offering … Continued

Palo Alto, CA, October 3, 2018 – Kodiak Sciences Inc. (“Kodiak”) today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $10.00 per share. In addition, Kodiak has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares … Continued

Palo Alto, CA, September 24, 2018 – Kodiak Sciences Inc. (“Kodiak”) today announced that it has launched an initial public offering of 9,000,000 shares of its common stock at an anticipated initial offering price between $13.00 and $15.00 per share pursuant to a registration statement on Form S-1 (the “Registration Statement”) filed with the U.S. … Continued

Palo Alto, CA, September 17, 2018 – Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced the appointment of Jason S. Ehrlich, M.D., Ph.D., as Chief Medical Officer and Chief Development Officer. Dr. Ehrlich joins other recent key additions to Kodiak’s leadership team: Almas … Continued

Palo Alto, CA, September 7, 2018 – Kodiak Sciences Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering … Continued

Palo Alto, CA, August 31, 2018 – Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that enrollment of patients in the company’s phase 1 safety and tolerability study has been completed. First patient in was dosed on July 12, 2018 and last patient … Continued

Palo Alto, CA, July 18, 2018 – Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced the appointments of Bassil I. Dahiyat, Ph.D., Robert A. Profusek, J.D., and Richard S. Levy, M.D. to its Board of Directors. “We are pleased to welcome Bassil, Bob, … Continued

Kodiak’s Antibody Biopolymer Conjugate platform and lead candidate KSI-301 to be highlighted Palo Alto, CA — April 27, 2018 – Kodiak Sciences Inc., a development-stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that presentations on its research will be made at the Association for Research in Vision and … Continued

Proceeds to Support Development of KSI-301 in Retinal Diseases Palo Alto, CA, April 26, 2018 – Kodiak Sciences Inc., a development-stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced the completion of a $33 million mezzanine private financing of convertible notes. Perceptive Advisors and ArrowMark Partners joined existing investors … Continued

Kodiak’s novel antibody bioconjugate candidates merge the science of biologics- and chemistry-based therapies Lonza to use expertise in biologics and chemistry to develop and manufacture clinical material at multiple sites across Europe and Asia Basel (CH) and Palo Alto, CA (USA), 08 February 2016 – Lonza, a global leader in biological and chemical manufacturing, and Kodiak Sciences Inc., … Continued